Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8280929 | 0.80 | HRH4 (0.36) | TLR9TLR8TLR7 | |
| SCHEMBL18965275 | 0.78 | HRH3 (0.36) | TLR9TLR8TLR7PARP1HRH3 | |
| SCHEMBL81385 | 0.75 | WNT3A (0.38) | TLR9TLR8TLR7 | |
| SCHEMBL2629282 | 0.74 | DDB1 (0.36) | — | |
| SCHEMBL23483118 | 0.74 | HRH3 (0.40) | TLR9TLR8TLR7PARP1HRH3 | |
| SCHEMBL17896394 | 0.74 | KDM5A (0.48) | TLR9TLR8TLR7PARP1HRH3 | |
| SCHEMBL16218245 | 0.73 | PARP1 (0.41) | TLR9TLR8TLR7PARP1HRH3 | |
| SCHEMBL21038286 | 0.71 | HRH3 (0.45) | TLR9TLR8TLR7HRH3KCNH2 | |
| SCHEMBL3072050 | 0.71 | OPRM1 (0.45) | TLR9TLR8TLR7PARP1HRH3 | |
| SCHEMBL171140 | 0.71 | HRH3 (0.36) | TLR9TLR8TLR7PARP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TLR9 4713/4885TLR8 4318/4885TLR7 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.